STOCK TITAN

Cytokinetics Inc. - CYTK STOCK NEWS

Welcome to our dedicated page for Cytokinetics news (Ticker: CYTK), a resource for investors and traders seeking the latest updates and insights on Cytokinetics stock.

Cytokinetics Inc. (symbol: CYTK) is a leading biopharmaceutical company focused on the discovery, development, and commercialization of pioneering muscle activators. With a primary goal of addressing debilitating diseases where muscle performance is compromised, Cytokinetics is at the forefront of muscle biology research.

Specializing in muscle function and contractility, Cytokinetics has developed small molecule drug candidates aimed at enhancing muscle performance. The company’s innovative treatments target diseases such as amyotrophic lateral sclerosis (ALS), heart failure, spinal muscular atrophy (SMA), and chronic obstructive pulmonary diseases (COPD).

Some of the key investigational medicines in the pipeline include:

  • CK-4021586 (CK-586): A cardiac myosin inhibitor showing promise in the treatment of cardiac diseases.
  • Aficamten: Designed to improve heart muscle function in chronic heart failure patients.
  • Omecamtiv Mecarbil: Another advanced therapy aimed at boosting heart muscle performance.

With a strong emphasis on improving the quality of life for patients with severe cardiovascular and neuromuscular diseases, Cytokinetics is committed to groundbreaking research and development. The company's strategic partnerships and collaborations support its mission to bring effective treatments to market, providing hope to patients worldwide.

Recently, Cytokinetics has been actively engaged in investor events and webcasts, sharing forward-looking statements and updates about its latest achievements and ongoing projects. The company's commitment to transparency and investor relations has established it as a reliable entity in the biopharmaceutical industry.

For more detailed updates and news, visit here, here, here, and here.

For investor inquiries, please contact Diane Weiser, Senior Vice President of Corporate Affairs, at (415) 290-7757.

Rhea-AI Summary
Cytokinetics presents baseline characteristics of patients in SEQUOIA-HCM trial
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.39%
Tags
none
-
Rhea-AI Summary
Cytokinetics, Incorporated (Nasdaq: CYTK) will host a virtual Investor and Analyst Day on Thursday, October 19, 2023, featuring presentations on New Horizons in Hypercontractility.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.39%
Tags
conferences
-
Rhea-AI Summary
Cytokinetics, Incorporated granted stock options to new employees as a material inducement to their employment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.63%
Tags
none
Rhea-AI Summary
Cytokinetics to present at HCMS Scientific Sessions and HFSA Annual Scientific Meeting on October 6-9, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.59%
Tags
conferences
-
Rhea-AI Summary
Cytokinetics announces call for proposals for the sixth annual Cytokinetics Communications Grant Program, offering $100,000 in support of patient advocacy organizations focused on cardiovascular and neuromuscular diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.94%
Tags
none
-
Rhea-AI Summary
Cytokinetics to participate in investor conferences in September
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.5%
Tags
conferences
Rhea-AI Summary
Cytokinetics opens enrollment for Phase 3 clinical trial of aficamten in patients with non-obstructive hypertrophic cardiomyopathy (nHCM)
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.85%
Tags
-
Rhea-AI Summary
Cytokinetics grants stock options to new employees
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.33%
Tags
none
-
Rhea-AI Summary
Cytokinetics reports financial results for Q2 2023, completes enrollment in SEQUOIA-HCM trial, reduces projected spending by 15%, and revises 2023 financial guidance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.7%
Tags
Rhea-AI Summary
Cytokinetics, Incorporated (CYTK) Grants 60,200 Stock Options to New Employees as Material Inducement
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.37%
Tags
none

FAQ

What is the current stock price of Cytokinetics (CYTK)?

The current stock price of Cytokinetics (CYTK) is $47.86 as of January 23, 2025.

What is the market cap of Cytokinetics (CYTK)?

The market cap of Cytokinetics (CYTK) is approximately 5.4B.

What does Cytokinetics Inc. specialize in?

Cytokinetics Inc. specializes in developing muscle activators for the treatment of diseases characterized by reduced muscle function, such as ALS and heart failure.

What are some key drug candidates being developed by Cytokinetics?

Key drug candidates include CK-4021586 (CK-586), Aficamten, and Omecamtiv Mecarbil, all aimed at enhancing muscle function and contractility.

Which diseases are targeted by Cytokinetics' treatments?

Cytokinetics' treatments target diseases like amyotrophic lateral sclerosis (ALS), heart failure, spinal muscular atrophy (SMA), and chronic obstructive pulmonary diseases (COPD).

What recent achievements has Cytokinetics announced?

Recent achievements include updates on CK-4021586 (CK-586), participation in investor events, and forward-looking statements on new developments.

How does Cytokinetics contribute to muscle biology research?

As a leader in muscle biology, Cytokinetics focuses on discovering and developing small molecule drugs designed to increase muscle function and contractility.

Who can be contacted for investor relations at Cytokinetics?

For investor relations, contact Diane Weiser, Senior Vice President of Corporate Affairs, at (415) 290-7757.

Where can I find more detailed updates and news about Cytokinetics?

More updates and news can be found on the GlobeNewswire website with provided links in the detailed company description.

What is the focus of Cytokinetics’ investigational medicines?

The focus is on muscle-directed medicines that potentially improve the health span of patients with severe cardiovascular and neuromuscular diseases.

What makes Cytokinetics' approach unique?

Cytokinetics' approach is unique due to its focus on muscle biology and the development of small molecule drugs specifically engineered to enhance muscle function.

What platforms does Cytokinetics use for investor communication?

Cytokinetics uses investor events, webcasts, and platforms like GlobeNewswire to communicate with investors.
Cytokinetics Inc.

Nasdaq:CYTK

CYTK Rankings

CYTK Stock Data

5.38B
115.63M
0.54%
118.15%
11.63%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SOUTH SAN FRANCISCO